A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of WIN-1001X for its therapeutic
confirmatory study by comparing and evaluating the efficacy and safety of each dose group by
conducting a therapeutic exploratory study on three dose groups of WIN-1001X 400 mg, 800 mg,
and 1200 mg, and placebo group in patients with early Parkinson's disease.